Foghorn Therapeutics Inc.
NASDAQ:FHTX

Watchlist Manager
Foghorn Therapeutics Inc. Logo
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Watchlist
Price: 7.52 USD -4.81% Market Closed
Market Cap: 418m USD
Have any thoughts about
Foghorn Therapeutics Inc.?
Write Note

EV/FCFF
Enterprise Value to FCFF

-1.5
Current
-0.4
Median
3.6
Industry
Lower than median
Lower than industry value

Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

EV/FCFF
-1.5
=
Enterprise Value
150.7m USD
/
FCFF
-103.8m USD
All Countries
Close
Market Cap EV/FCFF
US
Foghorn Therapeutics Inc.
NASDAQ:FHTX
418.1m USD -1.5
FR
Pharnext SCA
OTC:PNEXF
6T USD -236 926.9
US
Abbvie Inc
NYSE:ABBV
320.1B USD 23.8
US
Amgen Inc
NASDAQ:AMGN
147.4B USD 31.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD -82.6
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD 10.9
US
Epizyme Inc
F:EPE
94.1B EUR -473.4
AU
CSL Ltd
ASX:CSL
135.4B AUD 64.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 22.8
US
Seagen Inc
F:SGT
39.3B EUR -57.1
NL
argenx SE
XBRU:ARGX
34.3B EUR -101.3
 
US
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Average EV/FCFF: 30.6
Negative Multiple: -1.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -236 926.9
US
Abbvie Inc
NYSE:ABBV
23.8
US
Amgen Inc
NASDAQ:AMGN
31.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -82.6
US
Gilead Sciences Inc
NASDAQ:GILD
10.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -473.4
AU
CSL Ltd
ASX:CSL
64.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
22.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.1
NL
argenx SE
XBRU:ARGX
Negative Multiple: -101.3

EV/FCFF Forward Multiples

Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/FCFF
N/A
2-Years Forward
EV/FCFF
N/A
3-Years Forward
EV/FCFF
N/A

See Also

Discover More